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Midazolam sedation to produce complete amnesia 
for bronchoscopy: 2 years’ e perience at a district 
general hospital 
T. J. WILLIAMS AND P. E. BOWIE 
Kettering General Hospital NHS Trust, U.K. 
Patients may find bronchoscopy without sedation unpleasant. There is some evidence that patient satisfaction 
correlates with amnesia for the procedure. For several years we have used doses of midazolam sufficient to put 
patients lightly asleep hoping to produce complete amnesia. We looked at practical aspects of this technique over a 
2-year period. 
We studied 337 consecutive patients. They were 219 men and 118 women of mean age 63 f 12.4 (SD). Sixty-seven 
patients were aged 75 years or over and the eldest was 86. Sixty-three patients were already hospital inpatients but 
the remainder were seen as day cases. Midazolam was given by slow i.v. injection over several minutes until the 
patient was judged to be lightly asleep. Patients were given supplemental oxygen (3 1 min - ‘) and monitored by ECG 
and pulse oximetry. A note was made of the time at which they awakened, defined as when nursing staff felt the 
patients were awake enough to have a cup of tea and toast. Patients were asked if they had any memory of the 
procedure both on awakening and when seen a few days later to discuss the results. The procedures were carried out 
in a well-staffed Day Case Unit with a recovery area. 
The mean dose of midazolam used was 10.8 mg (mean i s~=O.16 * 0.095 mg kg - I). The midazolam was given 
over a median of 4 min (range l-15 min). Patients took 59 & 45 min (mean + SD) to wake up. Twenty-eight patients 
were given flumazanil to reverse the sedation (11 for concern over bleeding following biopsies, three for desaturation 
during and three after procedure, four as they were frail; two as they were restless, two as they were hypotensive after 
procedure and three for miscellaneous reasons). Only nine patients could remember any part of the procedure. 
Incremental doses of midazolam given slowly until patients are lightly asleep almost invariably produce complete 
amnesia for bronchoscopy. This is a safe technique but patients need careful monitoring and may require reversal 
of sedation with flumazanil. 
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Introduction 
Patients may find bronchoscopy unpleasant (l-3). There is 
some evidence that patient satisfaction correlates with 
amnesia for the procedure (4-7). For several years, there- 
fore, we have used intravenous midazolam in doses suffi- 
cient to put patients lightly asleep, hoping to produce 
complete amnesia for the procedure. We have previously 
described our experience (7) using an average dose of 
0.24 mg kg - ‘, but over the years have tended to use 
smaller doses, while still aiming to put patients asleep. We 
looked at practical aspects of this technique over a 2-year 
period. 
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Methods 
We studied 337 consecutive patients undergoing a fibre- 
optic bronchoscopy between February 1996 and 1998. 
Sixty-three patients were already inpatients but the remain- 
der were treated as day cases. Patient details are given in 
Table 1. 
No patient was taking anticoagulants but aspirin therapy 
was not discontinued in those patients already on it. A 
coagulation screen was not routinely performed before the 
procedure. 
Patients were given no premeditation. The procedure 
consisted of approximately 5 ml of 1% lignocaine jelly 
placed into each nostril and then administration of 
midazolam by slow intravenous (iv.) injection through an 
indwelling catheter over several minutes until the patient 
was judged to be lightly asleep, i.e. eyes closed, not respond- 
ing to speech nor a mildly painful stimulus (rubbing on the 
sternum). Patients were given supplemental oxygen at 
3lmin-’ by nasal prongs. This was usually directed into 
the mouth, except in eight patients in whom it proved 
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TABLE 1. Patient and midazolam details 
Total patients (n) 337 
Men (n) 219 
Women (n) 118 
Mean age ( f SD) .63 & 12.4 
Range 23-86 
Aged 75 and over (n) 67 
Mean dose of midazolam Men Women 
mg 10.8 10.8 
Range 3-32.5 2.5-45 
w kg -‘&SD 0.15 zk 0.08 0.18 f 0.12 
Combined male and female f SD 0.16 & 0.095 
Timing (min) Mean Median Range 
Length of midazolam injection 4.36 4.0 1-15 
Length of bronchoscopy 13.8 14 3-35 
Time to awakening (from end of bronchoscopy) 59 49 4-319 
impossible to pass the bronchoscope through the nose. For 
these patients the bronchoscope was inserted through the 
mouth and the oxygen directed into the nostrils. Patients 
were monitored for oxygen saturation, pulse rate and 
possible arrhythmias (Nellcor monitor MDE escort E300; 
Nellcor Puritan Bennett UK, Ltd; Oxon, UK). Alarms were 
set to go off if the saturation fell below 90% or the pulse was 
below 55 or above 130. 
We sprayed 4 ml of 2% lignocaine onto the vocal cords 
before the bronchoscope was passed through the larynx and 
2 ml aliquots of 2% lignocaine were used to control 
coughing. 
A note was made of the times (to the nearest min) of the 
start of the midazolam injection, beginning and end of the 
bronchoscopy and when the patient awoke (defined as 
when nursing staff felt the patient was awake enough to 
have a cup of tea and toast). Patients were asked if they had 
any memory of the procedure both shortly after awakening 
and again when seen to discuss the results, usually a few 
days later. 
The procedures were carried out in a well-staffed Day 
Case Unit. There were at least two and usually three nurses 
available to help in the endoscopy room. After bron- 
choscopy patients were monitored in a recovery area and 
supplemental oxygen continued until the patients were 
awake. Full resuscitation facilities were available. 
All patients had been advised not to drive themselves home 
nor to spend the night following the bronchoscopy alone. 
In patients suspected of having lung cancer, samples were 
taken in the following order: brushings for cytology; 
biopsies (at least six), washings for cytology. Trans- 
bronchial and transbronchial needle aspiration biopsies 
were not taken. However, when the bronchoscopy findings 
were normal but the chest X-ray suggested lung cancer, 
biopsies were taken blindly from the segment of the 
bronchial tree in which the abnormality was suspected. 
Some of these would go through the bronchial wall and 
therefore be ‘transbronchial’. 
The study was approved by our local Ethical Committee. 
Results 
All bronchoscopies except two were successfully completed. 
One patient proved impossible to sedate adequately. 
In another bleeding following biopsy necessitated abandon- 
ing the procedure and reversing the sedation with 
flumazenil. 
Details of midazolam dosage and timing are given in 
Table 1. 
Total doses were similar for men and women (two- 
sample t-test; P=O.95), but higher for the latter on a mg 
kg-’ basis (P=O.O16). Patients aged 75 years and over 
received smaller doses than younger patients (0.13 VS. 
0.17 mg kg- ‘; P=O.O004). For this age group, doses of 
midazolam were similar for men and woman whether 
expressed as total dose (mean 7.46 VS. 7.95 mg; PzO.77) or 
mg kg-’ (mean 0.12 VS. 0.15; PzO.27). Length of injection 
was similar for men and women (means=4.5 vs. 4.2 min; 
P=O.29). There was a negative correlation between dose in 
mg kg-’ and age for both men and women (Pearson’s 
correlation coefficient= - 0.418 and - 0.407; P~O.001 for 
both). 
For women there was a positive correlation between the 
dose of midazolam in mg kg- ’ and time taken to awaken 
(Pearson’s correlation coefficient = 0.27; P= ~0.01) but not 
for men (0.079; P>O.2). 
Nine patients (two men, seven women; mean age 62.3 
years, range 48-8 1) had some memory of the procedure, six 
on awakening and three when seen a few days later, 
although by then only one of the original six could remem- 
ber any of the procedure. 
One patient, when questioned just after the procedure, 
thought that he could remember the entire process, but a 
few days later could remember only some coughing. Other 
patients remembered some aspects, e.g. pain in the nose, a 
scraping sensation, coughing or some struggling. The doses 
used in these nine patients (0.12 & 0.029 mg kg - ‘) were 
similar to doses in other patients who had no memory of 
the procedure, although when comparing these nine 
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TABLE 2. Patients who were admitted following TABLE 3. Patients given flumazenil to reverse sedation 
bronchoscopy (n=28) 
Total 
Mean age (years) 
Range 
Mean dose of midazolam (mg) * SD 
Range 
mgkg-‘*SD 
Range 
Reason for admission (n) 
Chest pain due to metastases 
Shortness of breath secondary to 
pleural effusion 
*Severe bleeding after biopsy 
Bleeding plus atria1 arrhythmia 
Bleeding 
Desaturation post-procedure plus 
social factors 
Bleeding plus social factors 
Uncertain (notes missing) 
11 (seven men; 
four women) 
67.6 
59-82 
X.8 * 3.2 
3.5-14.0 
0.12 5 0.043 
0.06-0.2 
1 
2 
2 
1 
1 
2 
*Procedure abandoned. 
patients to the whole group, significantly lower doses had 
been used (P=O.O008). 
Eleven out of the original 274 day case patients were 
admitted following the bronchoscopy. Details are given in 
Table 2. Overall these patients were given smaller doses of 
midazolam than the whole group (0.12 VS. 0.16 mg kg- ‘; 
P=O.O13). 
Flumazanil was used to reverse sedation in 28 patients. 
The dose of flumazanil used was between 250 and 500 mcg, 
with most patients receiving 500 mcg. Details are given in 
Table 3. Patients given flumazanil tended to be given 
smaller doses of midazolam than patients who were not 
(mean 0.14 vs. 0.16mg kg-‘; P=O.27) and were older 
(mean age 70.2 VS. 62.9 years; P=O,OOO9). Of the four 
patients who were hypotensive post-procedure two were 
taking diltiazem, two ACE inhibitors, and all four diuretics. 
Of patients admitted or given flumazanil because of 
bleeding, all except three had biopsies. None had a clear 
history of alcohol excess but three had abnormal liver 
function tests. One was taking aspirin. 
We looked separately at patients given 20 mg or more of 
midazolam (approximate mean +2 SD). Details are given in 
Table 4. Compared to patients given lower doses, they were 
not heavier (mean weight 69.9 vs. 69.5 kg; P=O.88), but 
were much younger (mean age 48.9 vs. 64.5 years; 
P=O.OOOO). They tended to take longer to awaken (mean 
85.1 vs. 56.6 min; P=O.ll). The midazolam injections were 
given over a longer period than for patients with lower 
doses (mean 6.6 vs. 4.2min; P=O.O007) but in only four 
patients was the injection given over 10 min or more. In two 
patients the sedation was reversed with flumazanil, because 
they seemed particularly restless post-procedure. None of 
these patients needed admission. Four were taking regular 
benzodiazepines, four opiods and 14 (including two on 
Men (n) 
Women (n) 
Mean age (years) 
Range 
Mean dose of midazolam (mg) & SD 
Range 
mg kg -'&SD 
Range 
Reasons for reversal (n) 
Bleeding after biopsy 
Bleeding and desaturation 
Bleeding and frail 
Desaturation during procedure 
Frail elderly patients 
Desaturation post-procedure 
Desaturation and hypotension 
post-procedure 
Hypotension post-procedure 
Low platelet count (no bleeding) 
Tracheostomy 
Shortness of breath due to pleural effusion 
Restless post-procedure 
18 
10 
70.2 
51-82 
8.4 * 5.4 
2.5-26 
0.14 i 0.09 
0.05-0.47 
6 
2 
3 
4 
2 
TABLE 4. Patients given 20 mg or more of midazolam 
(n=28) 
Men (J-Z) 
Women (n) 
Mean age (years) 
Range 
Mean dose of midazolam (mg) f SD 
Range 
mg kg-‘&SD 
Range 
Mean time to awakening (min) f SD 
Range 
Mean length of injection (min) +C SD 
Range 
18 
10 
48.9 
26-75 
25.3 k 5.7 
20-45 
0.38 + 0.13 
0.23-0.65 
85 z’r 83.6 
5-319 
6.6 * 3 
4-15 
benzodiazepines) had a history suggestive of excess alcohol 
consumption. Of these, 10 had abnormal liver function 
tests. 
The group included one woman who was a known 
alcoholic in whom it proved impossible to achieve adequate 
sedation, even when giving 45 mg total dose over a period 
in excess of 15 min. 
Of the patients, 131 were found to have lung cancer and 
the remainder a variety of non-malignant conditions. 
Discussion 
We have shown over a 2-year period that patients can be 
safely sedated for bronchoscopy with incremental doses of 
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midazolam given over several minutes until they are judged 
to be lightly asleep. However, we carried out the procedures 
in a well-staffed day case unit with a recovery area and full 
resuscitation facilities. 
Using this technique, patients rarely have any memory of 
the procedure. It is not clear why a small number (less than 
3%) could remember part of it. Although they were given 
smaller doses of midazolam than the group as a whole, the 
doses were similar to those given to other patients who 
remembered nothing and they were all judged to be lightly 
asleep at the onset of the procedure. None of these patients 
were known to have other factors which might have 
influenced the metabolism of midazolam, such as an excess 
alcohol intake or concomitant use of benzodiazepines or 
rifampicin(8). 
Little is known about patients’ fears concerning 
bronchoscopy, although a Malaysian study (9) showed that 
over 80% of patients preferred to be sedated and only rarely 
did patients have a fear of sedation. However, no studies 
have been carried out comparing patients’ views of 
bronchoscopy while unsedated compared to bronchoscopy 
under sedation given in sufficient doses to produce complete 
amnesia, but there is a suggestion both for endoscopy (4,5) 
and bronchoscopy (6,7) that patient acceptability correlates 
with the level of amnesia for the procedure. 
We admitted 11 out of 274 patients in whom the pro- 
cedure had been planned as a day case. Of these, two were 
for pre-existing conditions (chest pain due to metastases 
and a pleural effusion) but most were due to concern over 
bleeding following biopsies. The sedation technique may 
have contributed to the admission of five patients; two 
desaturated in association with bleeding and the develop- 
ment of atria1 fibrillation, two patients desaturated associ- 
ated with bleeding and one desaturated after the end of the 
procedure. Social factors contributed to the decision to 
admit at least two of the patients. 
Flumazanil was used to reverse sedation in 28 patients, 
usually because of concern over bleeding, but also in four 
patients who were hypotensive post-procedure. Drug 
interactions, including diltiazem which inhibits the metab- 
olism of midazolam (8), may also have contributed. We 
admitted four elderly patients who seemed particularly 
frail. Although flumazanil has a shorter half-life than 
midazolam and resedation may occur (10) we found a 
second dose of flumazanil to be necessary in only one 
patient. 
During the procedure we used boluses of lignocaine to 
suppress coughing which made the procedure difficult for 
the operator. We did not keep records of the precise dose 
used, but the technique was identical to that which we have 
used for some years and described previously (11) therefore 
the doses were unlikely to be excessive. 
Complications may be more common when bron- 
choscopy is carried out in patients with severe obstructive 
pulmonary disease (12). Our study does not allow us to 
draw any conclusions about the safety of midazolam seda- 
tion in this group of patients. We used the same technique 
for all patients undergoing a bronchoscopy, while 
spirometry was often not available. Over the 2-year period 
bronchoscopy was not carried out in a few patients who 
were judged by the operator (T.J.W.) to be high-risk, e.g. 
patients who looked particularly frail or who were required 
continuous oxygen therapy. The decision not to perform 
bronchoscopy was usually based on a subjective clinical 
impression rather than objective data. 
One disadvantage of the technique is that some patients 
take a long time to awaken. This may reflect the prolonged 
elimination half-life of midazolane which occurs in some 
patients (13). It is not clear why there was a better corre- 
lation between dose and time to awakening in women than 
in men. 
Alcohol intake and liver function may influence the 
clinical effect of midazolam. These factors were not known 
in all our patients. However, in the group requiring 20 mg 
or more of midazolam, at least half had a history suggestive 
of excessive alcohol consumption. 
Our study does not allow us to draw conclusions as to the 
minimum dose that can be used to produce complete 
amnesia. We have previously shown that a higher dose 
(mean 0.24 mg kg- ‘) (7) invariably produces amnesia. 
Other studies showed that 0.05 mg kg-’ for fibreoptic 
bronchoscopy (14) rigid bronchoscopy (15) and endoscopy 
(4) frequently did not produce amnesia. Similarly, 0.07 mg 
kg- ’ for endoscopy (16) and 0.1 mg kg ~ ’ for rigid 
bronchoscopy (15) again did not always produce amnesia, 
although a higher dose (mean 0.17 mg kg-‘) used for 
fibreoptic bronchoscopy did (17). This latter dose is similar 
to the dose used in our present study. 
It is not certain how to assess clinically when a patient 
has had a sufficient dose of midazolam to produce complete 
amnesia. In this study we chose the point at which the 
patient seemed to be lightly asleep, as when using higher 
doses (7) we had shown this clinical feature to correlate 
with complete amnesia. Complete amnesia was produced 
giving incremental doses up to the onset of ptosis (17) but 
in this study additional maintenance doses were given 
during the procedure. Another endoscopy study (5) which 
used the clinical signs of onset of slurred speech, nystagmus 
or ptosis, only produced complete amnesia in 73% of 
patients. Additional doses were also sometimes given 
during the procedure. 
An important aspect of giving intravenous midazolam 
may be the speed of the injection. The blood-brain 
equilibration is slow (18) and may take up to 3 min for 
maximum effect (19). Therefore, it may be best to give 
midazolam in small incremental doses and waiting 2-3 min 
between each dose. Although we deliberately tried to give 
the injection slowly over several minutes, the median time 
was only 4 min and it is possible that we might have been 
able to produce complete amnesia with lower doses given 
more slowly. This might also have avoided the particularly 
high doses given to some patients. However, in a study 
of only 20 patients who were given small doses at 2-minute 
intervals, the total doses required (induction plus 
maintenance doses) were similar to those used in our 
study (17). 
In summary, we have shown over a 2-year period that 
incremental doses of midazolam given until a patient is 
lightly asleep is a safe technique for bronchoscopy and 
almost invariably produces complete amnesia. However, 
patients need careful monitoring and may require reversal 
of sedation with flumazanil. 
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